Pharmacological profile of antidepressants and related compounds at human monoamine transporters.

Using radioligand binding assays, we determined the equilibrium dissociation constants (KD's) for 37 antidepressants, three of their metabolites (desmethylcitalopram, desmethylsertraline, and norfluoxetine), some mood stabilizers, and assorted other compounds (some antiepileptics, Ca2+ channel antagonists, benzodiazepines, psychostimulants, antihistamines, and monoamines) for the human serotonin, norepinephrine, and dopamine transporters. Among the compounds that we tested, mazindol was the most potent at the human norepinephrine and dopamine transporters with KD's of 0.45 +/- 0.03 nM and 8.1 +/- 0.4 nM, respectively. Sertraline (KD = 25 +/- 2 nM) and nomifensine (56 +/- 3 nM) were the two most potent antidepressants at the human dopamine transporter. We showed significant correlations for antidepressant affinities at binding to serotonin (R = 0.93), norepinephrine (R = 0.97), and dopamine (R = 0.87) transporters in comparison to their respective values for inhibiting uptake of monoamines into rat brain synaptosomes. These data are useful in predicting some possible adverse effects and drug-drug interactions of antidepressants and related compounds.

[1]  S. Ross,et al.  Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue. , 1969, European journal of pharmacology.

[2]  E. Richelson,et al.  Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. , 1984, European journal of pharmacology.

[3]  V. Ganapathy,et al.  Sodium- and chloride-dependent, cocaine-sensitive, high-affinity binding of nisoxetine to the human placental norepinephrine transporter. , 1993, Biochemistry.

[4]  L. Jellett,et al.  Log-normal distribution of equiefective doses of norepinephrine and acetylcholine in several tissues. , 1972, The Journal of pharmacology and experimental therapeutics.

[5]  E. Richelson,et al.  Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. , 1993, Life sciences.

[6]  R. Shank,et al.  Preclinical evaluation of McN-5707 as a potential antidepressant. , 1987, The Journal of pharmacology and experimental therapeutics.

[7]  R. Blakely,et al.  Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. , 1996, Molecular pharmacology.

[8]  J. Glowinski,et al.  Inhibition of Uptake of Tritiated-noradrenaline in the Intact Rat Brain by Imipramine and Structurally Related Compounds , 1964, Nature.

[9]  J. Maas Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. , 1975, Archives of general psychiatry.

[10]  D. Williams,et al.  Two Affinity States for [3H]Imipramine Binding to the Human Platelet 5‐Hydroxytryptamine Carrier: An Explanation for the Allosteric Interaction Between 5‐Hydroxytryptamine and Imipramine , 1990, Journal of neurochemistry.

[11]  R. Kuhn The treatment of depressive states with G 22355 (imipramine hydrochloride). , 1958, The American journal of psychiatry.

[12]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[13]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[14]  Randy D. Blakely,et al.  Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter , 1991, Nature.

[15]  K. Fuxe,et al.  Intercellular communication in the brain: Wiring versus volume transmission , 1995, Neuroscience.

[16]  B. Koe Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. , 1976, The Journal of pharmacology and experimental therapeutics.

[17]  R. Mcgee,et al.  Inhibition of high affinity synaptosomal uptake systems by verapamil. , 1979, Molecular pharmacology.

[18]  S. Tejani-butt [3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. , 1992, The Journal of pharmacology and experimental therapeutics.

[19]  Oxman Te Antidepressants and cognitive impairment in the elderly. , 1996 .

[20]  E. Richelson Pharmacology of antidepressants--characteristics of the ideal drug. , 1994, Mayo Clinic proceedings.

[21]  P. Brust,et al.  Specific binding of [3H]imipramine indicates the presence of a specific serotonin transport system on endothelial cells of porcine brain , 1995, Neuroscience Letters.

[22]  A. Carlsson,et al.  Central and peripheral monoaminergic membrane‐pump blockade by some addictive analgesics and antihistamines , 1969, The Journal of pharmacy and pharmacology.

[23]  S. Hill,et al.  Inhibition by H1-antihistamines of the uptake of noradrenaline and 5-HT into rat brain synaptosomes. , 1988, Biochemical pharmacology.

[24]  R. Spealman,et al.  Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. , 1989, The Journal of pharmacology and experimental therapeutics.

[25]  R. Blakely,et al.  Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. , 1994, Molecular pharmacology.

[26]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[27]  R. Blakely,et al.  Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Kuhar,et al.  Methods in Neurotransmitter Receptor Analysis , 1990 .

[29]  E. Richelson Synaptic Effects of Antidepressants , 1996, Journal of clinical psychopharmacology.

[30]  M. Worcel,et al.  The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. , 1986, European journal of pharmacology.

[31]  K. Neve,et al.  Characterization of a recombinant human dopamine transporter in multiple cell lines. , 1995, The Journal of pharmacology and experimental therapeutics.

[32]  R. Lefkowitz,et al.  Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. , 1982, Molecular pharmacology.

[33]  M. Caron,et al.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.

[34]  S. Kish,et al.  Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. , 1994, Molecular pharmacology.

[35]  D. Gehlert,et al.  Comparison of (R)‐[3H] Tomoxetine and (R/S)‐[3H] Nisoxetine Binding in Rat Brain , 1995, Journal of neurochemistry.